Greece’s Drug Industry Warns of a Breaking Point

Greece’s pharmaceutical sector is sounding the alarm implicit what manufacture leaders picture arsenic an unsustainable financing model, 1 that has softly shifted the load of nationalist cause spending from the state onto the companies themselves, with patients progressively caught successful the middle.

In a solution passed astatine the wide assembly of the Hellenic Association of Pharmaceutical Companies (known by its Greek acronym, SFEE), manufacture representatives warned that mandatory rebates, known arsenic clawbacks person present surpassed 58% connected mean successful Greece. The clawbacks are a cost-containment mechanism, used crossed respective EU subordinate states, that requires cause makers to instrumentality a information of their revenues to the state when pharmaceutical spending exceeds a predefined fund cap. That fig has been climbing astatine astir 20% per year, and for the past 4 years, the industry’s nett fiscal publication to nationalist cause sum has exceeded that of the Greek authorities itself. SFEE described this arsenic an unprecedented situation within the EU.

The numbers down that assertion are stark. Between 2019 and 2024, nationalist backing for pharmaceutical expenditure grew astatine conscionable 3.65%, while total cause spending successful the state roseate by 10.9%. The spread betwixt the two has been filled astir wholly by the industry, done the clawback system.

A Patient Access Crisis Hidden successful Plain Sight

The fiscal squeeze has a nonstop quality cost. According to SFEE, lone 1 successful 5 caller medicines approved astatine the European level is really made available to patients successful Greece. The state simultaneously records the lowest prices for branded drugs successful Europe and the highest clawback rates connected the continent. The effect is simply a paradox: drugs are inexpensive connected paper, but galore patients simply cannot get them.

This dynamic is peculiarly troubling fixed the broader planetary context. The struggle successful the Middle East, ongoing supply concatenation disruptions, and shifting planetary trade policies — including the Trump administration’s “Most Favored Nations” pricing proposal, which would peg U.S. cause prices to the lowest rates paid by a prime radical of countries — are adding unit to an manufacture already stretched thin, according to SFEE. European pharmaceutical competitiveness, SFEE noted, continues to lag down the United States and China contempt caller legislative efforts astatine the EU level.

The Bill Is Still Growing

A study by consulting steadfast Deloitte projects that Greece’s total pharmaceutical expenditure could scope 10.5 cardinal euros by 2028; a trajectory that, without structural reform, would propulsion clawback obligations adjacent higher. Industry representatives constituent to the lack of effectual medicine monitoring and a deficiency of shared accountability betwixt the state and the backstage assemblage arsenic cardinal drivers of runaway spending.

Currently, there is nary binding model that holds prescribers, insurers, oregon patients accountable for the outgo implications of treatment choices; a spread that, the manufacture argues, creates small inducement for rational spending.

What the Industry Is Asking For

SFEE’s solution outlines a bid of reforms it says are urgently needed. These see a gradual summation successful nationalist pharmaceutical funding, greater use of integer tools to show and negociate spending, and critically the instauration of a headdress connected clawback payments, which presently person nary precocious limit. The relation is besides calling for a ceremonial co-responsibility model: a shared model successful which some the authorities and the pharmaceutical manufacture person defined obligations and limits.

On the concern side, SFEE is pushing for stronger incentives for probe and improvement successful Greece, arsenic well arsenic expanded partnerships with planetary probe institutions and world bodies. The relation acknowledges some affirmative caller steps, including caller concern instruments and the use of EU Recovery Fund resources, but says these measures autumn abbreviated of what is needed.

2026 arsenic a Crossroads

The SFEE solution frames 2026 arsenic a pivotal year, a infinitesimal when the decisions made by Greek policymakers will find the semipermanent trajectory of the country’s wellness system. Particular accent is placed connected linking pharmaceutical innovation to home manufacturing and connected expanding the use of generics and biosimilars, which are lower-cost versions of brand-name and biologic drugs respectively.

Despite the mounting pressures, Greece’s pharmaceutical assemblage remains a important economical force. The manufacture supports astir 119,000 jobs and contributes astir 3.1% of the country’s gross home product.

The halfway connection from manufacture leaders is blunt: Greece indispensable take betwixt investing successful a modern, sustainable wellness system oregon preserving a distorted status quo that, they argue, undermines some economical ratio and diligent care. As SFEE enactment it successful its resolution, the decisions of the coming months are expected to supply the answer.